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Background: Recent studies of botulinum toxin for post-stroke spasticity indicate
potential benefits of early treatment (i. e., first 6 months) in terms of developing
hypertonicity, pain and passive function limitations. This non-interventional, longitudinal
study aimed to assess the impact of disease duration on the effectiveness of
abobotulinumtoxinA treatment for upper limb spasticity.
Methods: The early-BIRD study (NCT01840475) was conducted between February
2013 and 2018 in 43 centers across Germany, France, Austria, Netherlands and
Switzerland. Adult patients with post-stroke upper limb spasticity undergoing routine
abobotulinumtoxinA treatment were followed for up to four treatment cycles. Patients
were categorized by time from stroke event to first botulinum toxin-A treatment in the
study (as defined by the 1st and 3rd quartiles time distribution) into early-, medium- and
late- start groups. We hypothesized that the early-start group would show a larger benefit
(decrease) as assessed by the modified Ashworth scale (MAS, primary endpoint) on
elbow plus wrist flexors compared with the late-start group.
Results: Of the 303 patients enrolled, 292 (96.4%) received ≥1 treatment and 186
(61.4%) received 4 injection cycles and completed the study. Patients in all groups
showed a reduction in MAS scores from baseline over the consecutive injection visits
(i.e., at end of each cycle). Although reductions in MAS scores descriptively favored
the early treatment group, the difference compared to the late group did not reach
statistical significance at the last study visit (ANCOVA: difference in adjusted means of
0.15, p = 0.546).
Conclusions: In this observational, routine-practice study, patients in all groups
displayed a benefit from abobotulinumtoxinA treatment, supporting the effectiveness of
treatment for patients at various disease stages. Although the data revealed some trends
in favor of early vs. late treatment, we did not find strong evidence for a significant benefit
of early vs. late start of treatment in terms of reduction in MAS scores.
Keywords: abobotulinumtoxinA, botulinum toxin, Dysport, spasticity, stroke
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INTRODUCTION
A significant percentage of patients develop upper limb spasticity
after stroke. In general, upper limb muscles are more affected
than lower limb muscles, with the arm being severely affected
in about 30% of stroke survivors (1–3). Spasticity interferes with
routine task performance, contributes to the development of
joint contractures and pain, makes hygiene, and self-care difficult
and ultimately has great impact on patient and caregiver quality
of life (QoL) (4–7). Spasticity may evolve early in the post-
stroke period, with one in five patients developing spasticity
within 3 months of the stroke event (8, 9). Some studies have
demonstrated muscle tone changes in the affected limbs within
just 3 weeks after the stroke event (10–12).
Botulinum neurotoxin A (BoNT-A), including
abobotulinumtoxinA (Dysport R©, Ipsen Pharma, Wrexham UK),
is recommended as a first-line pharmacological treatment option
for spasticity (13, 14), but is not typically initiated until spasticity
is well-established, and often much later (15). Systematic reviews
based on randomized, controlled trial evidence have confirmed
that BoNT-A is well-tolerated and effective for the treatment
of upper limb spasticity (16, 17). However, to date, most
interventional studies have been restricted to patient cohorts
with chronic spasticity (i.e., at least 6 months, and an average of
2.5 years post-stroke) (16–18). This limited evidence-base has
influenced current guidelines remaining unclear about treatment
goals considering different stages and severity of spasticity.
AbobotulinumtoxinA is approved for the management of adult
upper (and lower) limb spasticity. Recent randomized, placebo-
controlled data indicate potential benefits of early treatment
with abobotulinumtoxinA in terms of delaying development of
hypertonicity, reducing pain and passive function limitations
(18–20), and it has further been suggested that early injections
may be helpful in preventing contracture development, with
potential to unmask active functional improvement (18, 21).
Indeed, exploratory analyses of studies of abobotulinumtoxinA
in upper limb spasticity management have suggested that the
most influential factors predicting goal achievement are previous
treatment status (whether the patients were de novo or had been
previously treated with BoNT-A) and time since spasticity onset
as well as the spasticity pattern, and overall injection dose (22).
The aim of the early-BIRD (early Botulinum toxin treatment:
Initial and Repeated Documentation) study was to evaluate
the real-world effectiveness of abobotulinumtoxinA on the
evolution of spasticity in patients with post-stroke upper limb
spasticity according to the time from stroke to start of BoNT-
A treatment. We hypothesized that patients who start treatment
with abobotulinumtoxinA early in their treatment journey will
show a larger effect (i.e., reduction in spasticity from baseline) as
assessed by the composite sum of the modified Ashworth scale
(MAS) at the elbow and wrist flexors when compared to those
who start treatment later in their disease course.
METHODS
Study Setting
The early-BIRD study was an international, multicenter, non-
interventional, prospective, longitudinal study conducted in
303 post-stroke survivors undergoing treatment in 43 centers
specializing in outpatient spasticity treatment across Germany,
France, Austria, Netherlands and Switzerland. The study began
in February 2013, recruitment continued until February 2016,
and the study completed in February 2018. The study was
conducted in compliance with the Declaration of Helsinki,
the International Ethical Guidelines for Epidemiological Studies
and the International Society for Pharmacoepidemiology (ISPE)
Guidelines for Good Pharmacoepidemiology Practices (GPP);
it was registered at clinicaltrials.gov as NCT01840475. Ethics
approval was obtained from the relevant independent ethics
committee at each study center. All patients provided written
informed consent for trial participation, including specific
consent that they were willing to fill in the QoL questionnaire
(EQ-5D-3L) at three visits.
Since this was a non-interventional study, investigators were
asked to report adverse events (AEs) to the safety department
of the drug manufacturer using the usual local process for
such reactions.
Patients
Patients were recruited on an out-patient basis through the
participating specialist centers (BoNT-A clinics, rehabilitation
clinics, or neurological practices) where they were undergoing
routine assessment and treatment. Investigators recruited all
adult patients (aged at least 25 years old) with hemiparesis
and clinically relevant post-stroke upper limb spasticity who
consented to study participation during a pre-defined time-
frame. Eligible patients were either currently being treated with
a BoNT-product or considering starting treatment in line with
the local prescribing information and usual medical practice.
The decision to prescribe abobotulinumtoxinA was made prior
to and independently from the decision to enroll the patient
in this non-interventional study. Out-of-routine diagnostic or
therapeutic interventions were not permitted during this study.
Key exclusion criteria included: recurrent stroke, sensitivity to
abobotulinumtoxinA, or its excipients, any contraindications as
given in the local SmPC for Dysport R©, and current participation
in an interventional trial.
The maximum number of patients per center was 20.
Investigators were permitted to space the inclusions (e.g.,
inclusion of 1 patient after every 2, or 3, etc. patients) but had
to follow the same recruitment frequency until achievement of
the recruitment target.
Assessments
Study data collected as part of routine medical care were
captured using an electronic Case Report Form (eCRF). Aside
from the EQ-5D-3L which was self-completed by the patients
(with or without caregiver assistance), investigators were only
required to record outcome assessments they routinely perform
in their clinical practice. Thus, some sites did not complete
all sections contained within the eCRF. Patients were followed
for a maximum of 4 routine abobotulinumtoxinA treatment
cycles. The timing of assessments was in accordance with routine
medical practice for the investigator. Other than this, no specific
instructions on the timing of treatment were given in the
study protocol.
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The primary measurement of effectiveness was the modified
Ashworth Scale (23) (composite sum of elbow and wrist flexors;
MASEWF) at the end of treatment cycle 4 (visit 5) or last study
visit. The composite MASEWF is the sum of the MAS measured
at the elbow and at the wrist, which was chosen for this routine
practice study because is easier to perform than determining
a primary targeted muscle group. Other routine assessments
included demographics and relevant medical history, date of
stroke event, use of physical and occupational therapy, pattern of
upper limb spasticity involvement (24), passive and active Range
ofMotion (PROM and AROM) assessments, pain assessment [on
a visual analog scale [VAS] at rest], and treatment satisfaction, as
well as injection details (dose, muscles injected etc.). In addition,
many specialist centers routinely use a goal setting approach,
including Goal Attainment Scaling (GAS) to assess effectiveness
of the treatment (25, 26). Investigators negotiated and agreed
the main treatment goal(s) with the patient at the baseline visit.
As previously suggested (27), goals were categorized under the
following six domains: improvement of mobility, pain reduction,
ease of care and hygiene, support and ease of physiotherapy
(PT) and/or occupational therapy (OT), functional improvement
(with definition of individual functional goal) and other (to be
specified). Goal attainment was rated as “fully achieved,” “partly
achieved,” or “not achieved” at each visit. Investigators were asked
to report adverse drug reactions directly to the safety department
of the study sponsor.
Statistical Analyses
The study population included all patients who received ≥1
injection of abobotulinumtoxinA and had ≥1 valid MAS
measurement post-baseline. For the primary effectiveness
endpoint, patients were categorized into sub-groups (early-start,
medium-start or late-state) according to the first and third
quartiles time distribution (first quartile = early group; final
quartile = late group) since the stroke event until start of
BoNT treatment.
The primary effectiveness assessment (MAS) was analyzed
with an analysis of covariance (ANCOVA) where the model
included a start of treatment group (early/medium/late),
and baseline MAS value. Other potential prognostic
factors/covariates were tested for inclusion in the model in
a stepwise selection process. The first step was based on
univariate testing of candidate prognostic factors/covariates
(full list provided in the Table e1). All factors with a critical
significance level of 0.20 were included in the second step that
compared each retained variable against the other retained
variables (at the 0.001 level using Pearson correlation for
continuous variables, Chi-square test/Fisher’s exact test for
categorical variables and Kruskal–Wallis for mixed categorical
and continuous variables) to confirm that there was no strong
link between them. If independence was not met for two variables
(p < 0.001), the choice was done according to clinical relevance.
Retained variables after step 2 were included in the stepwise
multivariate model and kept if the p < 0.2. Patients categorized
as medium-start were included in the model, but the primary
comparison was between early-start and late-start.
Comparisons of (i) MASEWF at each study visit (Visits
2, 3, 4 and 5) and (ii) change in MASEWF scores at study
Visit 5, between early-start and late-start patients (with and
without stratification by previous BoNT exposure) were analyzed
as secondary effectiveness variables using a similar model
(ANCOVA including start-of-treatment group and baseline
MAS) as the primary effectiveness endpoint. Other endpoints
included descriptive analyses of MASEWF scores in the early,
medium and late group with (exploratory) and without
(secondary) stratification by BoNT exposure.
Between group differences in goal attainment and treatment
satisfaction were analyzed using proportional odds models
including treatment group as fixed effects. Changes in AROM,
PROM and pain from Visit 1 to Visit 5 were analyzed using an
ANCOVAwhere themodel included start of treatment group and
baseline values. Finally, changes from baseline in MAS and other
endpoints, including EQ-5D-3L, were summarized descriptively
by start of treatment group.
Sample Size Estimation
It was estimated that a total of 150 patients was required to
achieve 80% power in detecting an effect size of 0.5 on the
composite MAS between the early-start and late-start groups at
the 2-sided 5% significance level. To achieve a sample size of 150
patients in the early-start and late-start groups (75 in each group),
a total of 300 patients was required.
RESULTS
Patient Disposition and Baseline
Characteristics
Of the 303 patients enrolled, 257 (84.8%) received treatment and
had one post-baseline measurement of MAS, and 186 (61.4%)
received 4 injection cycles and completed the study. The most
common reason for early discontinuation was loss to follow-up
(Figure 1). Per protocol, the study population was categorized
into treatment groups: early-start n = 63, medium-start n = 126
and late-start n = 63; five patients were not categorized due to
lack of information. Baseline characteristics are given in Table 1,
overall 147 patients were previously-treated with a BoNT and 110
patients were naïve to BoNT treatment. Of note, the mean age at
inclusion was higher and the mean age at stroke was lower in the
late-start group vs. the other groups.
Treatment Exposure
The mean ± SD time from stroke until start of first BoNT-
A treatment was 3.74 ± 1.75 months in the early-start group,
20.11 ± 11.08 months in the medium-start group and 144.24 ±
90.85 in the late-start group. The time from documented onset
of spasticity to start of first BoNT-A treatment was 1–5 months
shorter than time since stroke; mean ± SD times since onset of
spasticity were 2.60 ± 1.96, 17.20 ± 11.76, and 138.63 ± 91.82
months, respectively.
Most patients (n = 190, 73.9%) received 4 injections of
abobotulinumtoxinA during the study period. Taken overall, the
mean total dose of abobotulinumtoxinA over the study was
743.08 ± 356.60U and the mean time between injections was
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FIGURE 1 | Patient disposition. *Five subjects in the study analysis population were not categorized in the start of treatment groups due to lack of information
reported in the eCRF.
TABLE 1 | Baseline (Visit 1) characteristics.
Early-start
N = 63
Medium-start
N = 126
Late-start
N = 63
Age (years); mean (SD) 59.70 (10.98) 60.58 (10.94) 62.25 (13.35)
Sex; n(%) male 41 (65.1) 89 (70.6) 30 (47.6)
Time since stroke event
to first treatment
(months); N, mean (SD)
[95%CI]
N = 62
3.74 (1.75)
[3.29, 4.18]
N = 126
20.11 (11.08)
[18.16, 22.06]
N = 63
144.24 (90.85)
[121.36, 167.12]
Time since arm spasticity
onset to first treatment
(months); N, mean (SD),
[95%CI]
N = 59
2.60 (1.96)
[2.09, 3.11]
N = 114
17.20 (11.76)
[15.02, 19.38]
N = 59
138.63 (91.82)
[114.70, 162.56]
Arm pattern; n (%)
Type I 11 (17.5) 16 (13.2) 4 (6.3)
Type II 0 3 (2.5) 4 (6.3)
Type III 24 (38.1) 52 (43.0) 23 (36.5)
Type IV 27 (42.9) 40 (33.1) 30 (47.6)
Type V 1 (1.6) 10 (8.3) 2 (3.2)
Missing 0 5 0
MASEWF score* 4.82 (1.39) 4.53 (1.55) 4.83 (1.36)
Pain on VAS 3.92 (3.05) 2.80 (2.83) 2.30 (2.81)
All available data is presented, including the number of patients who had available data
for each individual outcome. *Composite Modified Ashworth Scale (MAS) score = sum of
elbow and wrist flexors (MASEWF ). VAS, visual analog scale.
3.69 ± 1.27 months. Overall dose exposure per cycle by groups
is presented in Table 2. Mean ± SD total doses increased over
the course of the study; from 675.7± 308.6U to 718.9± 473.8U
in the early-start group, and from 745.3U ± 402.6U to 861.9U
± 401.6U in the late-start group. The overall (averaged) time
between study injections was longer in the early-start vs. late-start
group (3.70± 1.16 months vs. 3.46± 0.76 months).
TABLE 2 | AbobotulinumtoxinA exposure.
Early-start
N = 63
Medium-start
N = 126
Late-start
N = 63
Total dose (U)
throughout study;
Mean (SD)
Median [range]
N = 63
719.32 (338.5)
645.0 [150.0–1833.7]
N = 125
714.23 (342.2)
655.0 [220.0–2112.5]
N = 62
807.45 (402.7)
780.0 [100.0–1800.0]
Time between study
injections; (M)
Mean (SD)
Median [range]
N = 60
3.70 (1.2)
3.2 [2.1–7.4]
N = 125
3.78 (1.5)
3.3 [1.5–13.4]
N = 63
3.46 (0.8)
3.2 [2.7–6.1]
Length of exposure
(days)
Mean (SD)
Median [range]
N = 63
375.3 (169.6)
387.0 [58.0–1018.0]
N = 126
402.9 (140.1)
381.5 [92.0–1113.0]
N = 63
390.6 (136.7)
386.0 [87.0–1029.0]
Modified Ashworth Scale
Patients in all groups showed a reduction in MASEWF scores
from baseline over the consecutive injection visits (i.e., at
the end of each cycle) (Figure 2A). Although the primary
analysis showed a numerically lower MASEWF score (LS mean)
for the early- compared to the late- start treatment group
(3.72 ± 0.28 vs. 3.87 ± 0.28), the difference at V5/last
observed visit did not reach statistical significance (ANCOVA,
p= 0.5465) (Table 3).
Analysis by prior treatment showed that for the patients
who were previously BoNT-naïve, there was a numerically
larger reduction in the mean MASEWF scores in the early-
start (despite a slightly lower baseline) vs. late-start patients
from Visits 2 to 5 (Figure 2B); however differences were not
statistically significant in the ANCOVA model (p-values ranged
from 0.4788 to 0.8150). This clear pattern was not apparent in
those patients who had been previously treated with a BoNT prior
to study entry (Figure 2C). Previously treated patients showed
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FIGURE 2 | Descriptive statistics for MASEWF by study visit, early-start vs. delayed start subgroups (A) overall population, (B) BoNT-naïve population, and (C)
previously treated population. Study visits were at end of treatment cycle.
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TABLE 3 | Primary ANCOVA analysis.
Early-start group
(N = 52)
Late-start group
(N = 54)
Least square mean (SE)
MASEWF score
3.72 (0.28) 3.87 (0.28)
Difference in Least square
means
0.15
95% Confidence interval for
the difference
[−0.34, 0.64]
p-value 0.55
The final ANCOVA model included the following covariates: start of treatment group,
baseline MAS score, time since last injection before MAS assessment at V5 (days),
spasticity pattern at baseline, overall achievement of individual treatment goals,
concomitant therapy and average total dose (U).
lower MASEWF scores at baseline in both groups compared to
BoNT-naïve patients.
Goal Achievement
Analysis of baseline goal choice revealed that patients in the
early-start group appeared more likely to list pain reduction
as a key goal than those in the late-start group (54.0 vs.
39.7%, respectively) and functional improvement (38.1 vs. 27.0%,
respectively). Conversely, improving ease of care and/or hygiene
and supporting ease of PT and/orOT appeared to be chosenmore
frequently by patients with a longer duration of spasticity until
BoNT treatment. Similar proportions of patients in all groups
selected improvement of mobility as a treatment goal.
Overall at Visit 5, treatment goals were at least partially
achieved for all groups (Table 4). At most visits, there were no
significant differences in goal achievement between the early and
late-start groups. However, at Visits 2 and 3, the treatment goal
“functional improvement” was significantly better achieved in
the late than in the early-start group (p = 0.0179 and 0.0312,
respectively). At Visit 5, the treatment goals “Improvement of
mobility/flexibility” and “Support and ease of PT/OT” were
significantly better achieved in the early than in the late start of
treatment group (both p = 0.04). Whereas, the mean number of
hours per week for subjects using PT and/or OT decreased by
about an hour in the early start of treatment group (from 3.49 ±
3.23 h at baseline to 2.34 ± 1.41 h at Visit 5), it increased by over
an hour in the late start of treatment group (from 2.06 ± 1.37 h
at baseline to 3.30± 7.08 h at Visit 5).
Pattern of Upper Limb Spasticity
Involvement and Range of Motion
In terms of spasticity pattern, Types III and IV predominated at
each visit. There were no significant differences at Visits 3 (p =
0.18) or 5 (p = 0.06) in the type of spasticity pattern between
early-start and delayed-start groups.
Descriptive data for PROM and AROM at each visit are given
in Table 5. The only significant difference between groups was
PROM at the wrist joint at Visit 5, where the LS mean PROM
was significantly higher in the early-start group vs. the late-start
group (difference in LS mean −21.1 [95%CI: −38.7, −3.47],
TABLE 4 | Goal achievement.
Goal type Visit Early-
start
Medium-
start
Late-start
Improvement of
mobility/flexibility;
n (%)
Visit 2
Fully achieved
Partially achieved
Not achieved
Missing
8 (22.9%)
20 (57.1%)
7 (20.0%)
11
19 (22.1%)
58 (67.4%)
9 (10.5%)
8
7 (16.7%)
31 (73.8%)
4 (9.5%)
6
Visit 5
Fully achieved
Partially achieved
Not achieved
Missing
9 (47.4%)
9 (47.4%)
1 (5.3%)
0
22 (34.4%)
38 (59.4%)
4 (6.3%)
4
6 (18.2%)
25 (75.8%)
2 (6.1%)
3
Pain reduction; n (%) Visit 2
Fully achieved
Partially achieved
Not achieved
Missing
8 (32.0%)
14 (56.0%)
3 (12.0%)
8
16 (41.0%)
21 (53.8%)
2 (5.1%)
12
7 (33.3%)
11 (52.4%)
3 (14.3%)
4
Visit 5
Fully achieved
Partially achieved
Not achieved
Missing
3 (37.5%)
4 (50.0%)
1 (12.5%)
1
9 (30.0%)
17 (56.7%)
4 (13.3%)
3
7 (38.9%)
9 (50.0%)
2 (11.1%)
2
Ease of care and
hygiene; n (%)
Visit 2
Fully achieved
Partially achieved
Not achieved
Missing
8 (30.8%)
16 (61.5%)
2 (7.7%)
6
22 (38.6%)
30 (52.6%)
5 (8.8%)
9
13 (32.5%)
26 (65.0%)
1 (2.5%)
5
Visit 5
Fully achieved
Partially achieved
Not achieved
Missing
9 (64.3%)
4 (28.6%)
1 (7.1%)
0
20 (45.5%)
22 (50.0%)
2 (4.5%)
2
15 (50.0%)
14 (46.7%)
1 (3.3%)
3
Support and ease of
PT/OT; n (%)
Visit 2
Fully achieved
Partially achieved
Not achieved
Missing
9 (33.3%)
17 (63.0%)
1 (3.7%)
5
21 (35.0%)
37 (61.7%)
2 (3.3%)
6
9 (27.3%)
22 (66.7%)
2 (6.1%)
4
Visit 5
Fully achieved
Partially achieved
Not achieved
Missing
12 (75.0%)
3 (18.8%)
1 (6.3%)
0
24 (50.0%)
23 (47.9%)
1 (2.1%)
2
11 (39.3%)
17 (60.7%)
0
1
Functional
improvement; n (%)
Visit 2
Fully achieved
Partially achieved
Not achieved
Missing
2 (10.5%)
8 (42.1%)
9 (47.4%)
5
5 (12.5%)
29 (72.5%)
6 (15.0%)
8
1 (7.1%)
13 (92.9%)
0
3
Visit 5
Fully achieved
Partially achieved
Not achieved
Missing
1 (9.1%)
5 (45.5%)
5 (45.5%)
0
2 (7.1%)
21 (75.0%)
5 (17.9%)
3
2 (16.7%)
7 (58.3%)
3 (25.0%)
1
Other; n (%) Visit 2
Fully achieved
Partially achieved
Not achieved
Missing
0
2 (100.0%)
0
0
4 (66.7%)
1 (16.7%)
1 (16.7%)
0
1 (50.0%)
1 (50.0%)
0
0
Visit 5
Fully achieved
Partially achieved
Not achieved
Missing
1 (100.0%)
0 0
0
3 (60.0%)
2 (40.0%)
0
0
2 (66.7%)
1 (33.3%)
0
0
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TABLE 5 | Passive and active range of motion by visit.
Early-start Medium-start Late-start
ELBOW
PROM; N, Mean (SD)
Visit 1 40
105.63 (40.16)
79
107.25 (37.86)
42
105.07 (34.53)
Visit 3 32
112.50 (39.72)
69
109.20 (35.04)
36
103.75 (35.68)
Visit 5 20
107.50 (36.58)
58
118.36 (38.22)
29
102.24 (38.44)
AROM; N, Mean (SD)
Visit 1 25
66.20 (41.91)
52
70.19 (41.79)
30
68.87 (39.25)
Visit 3 21
70.00 (38.57)
50
68.50 (39.96)
24
78.42 (33.93)
Visit 5 12
66.67 (32.64)
35
72.29 (44.58)
18
63.33 (39.33)
WRIST
PROM; N, Mean (SD)
Visit 1 43
88.07 (38.22)
87
84.74 (36.01)
46
88.65 (34.81)
Visit 3 33
97.88 (31.08)
76
93.49 (33.33)
32
91.88 (35.05)
Visit 5 24
110.83 (37.41)
60
103.25 (33.02)
30
95.00 (37.55)
AROM; N, Mean (SD)
Visit 1 30
46.33 (31.10)
53
45.28 (29.03)
24
43.50 (27.86)
Visit 3 21
41.90 (21.12)
44
43.64 (24.50)
18
46.50 (29.90)
Visit 5 19
49.21 (38.12)
35
45.29 (31.53)
17
50.24 (44.56)
p= 0.02). Other changes in AROM and PROM at the wrist joint
were not significantly different between groups.
Pain
Patients in the early-start group reported higher pain scores
than those in the late-start group at baseline (3.92 vs. 2.30,
respectively). Whereas, patients in the early-start group showed
a trend to reduced pain, and particularly over the first injection
cycle, patients in the late-start group reported relatively stable
pain scores over time (Figure 3A). However, while LS mean of
pain scores tended to be lower in the early-start vs. late-start
group from Visits 3 to 5, the differences were not significant in
the ANCOVAmodel (p-value ranged from 0.055 to 0.196).
Quality of Life and Treatment Satisfaction
Stronger increases in the mean quality of life EQ-5D index scores
were observed in the early start of treatment group compared to
the late start of treatment group. In the early-start group, mean
EQ-5D index scores continuously increased from 0.54 ± 0.26 at
baseline to 0.72 ± 0.18 at Visit 5. Although mean EQ-5D index
scores in the late-start group also increased from 0.61 ± 0.31 at
baseline to 0.65± 0.26 at Visit 5, the increase was not continuous.
Overall, in all 5 dimensions, the percentage of subjects having
no problems increased for all dimensions between Visit 1 and
Visit 5 in the early-start group. By contrast, the percentage of
subjects having no problems tended to remain similar in the late-
start group (Figure e1). The main exception to this rule was pain,
which tended to improve in all groups, and particularly in the
early-start group. By Visit 5, no patient reported extreme pain in
the early-start group (vs. 15.9% at visit 1) (Figure 3B).
Satisfaction with treatment was good across treatment groups;
patients, investigators and caregivers were generally satisfied with
the treatment at Visits 3 and 5 (Figure 4). There were generally
no significant differences in treatment satisfaction between the
early-start and delayed-start groups, except for the investigator’s
satisfaction at Visit 3 which was significantly better for the late-
start group than for the early-start group (p= 0.047).
Safety
No new safety issues arose from the study. A total of 47 AEs were
reported, including 39 serious AEs in 21 patients. There were 7
deaths (myocardial infarction =1, cardiac arrest =1, cholangitis
=1, lung cancer progression =1, cause not reported =3), none
were considered treatment-related. Four of the 39 serious AEs
were considered potentially related to treatment (listlessness,
muscular weakness and two events of fall).
DISCUSSION
The results of this open-label, routine practice study did
not show an overall significant difference in tone when
abobotulinumtoxinA was started earlier (0–7 months) compared
to later (36–443 months) in the patient treatment journey.
Treatment with abobotulinumtoxinA was consistently effective
in reducing spasticity as well as spasticity/stretch- related
pain, whether started early after the stroke event or later,
indicating a continued benefit of repeated abobotulinumtoxinA
injections regardless of chronicity. MASEWF scores were,
however, descriptively lower in the early-start group than the
late-start group at each retreatment visit and at the end of study,
and this trendwas particularly apparent in patients whowere new
to BoNT-A treatment. No new safety findings emerged from this
study with doses up to 2,000 U.
Clinical guidelines recommend that spasticity is treated when
it becomes troublesome and impacts the patient’s life (14). The
similarity of baseline MAS scores between the three groups
confirm prior observations that clinically relevant spasticity
(as measured by muscle tone) develops in the first 3 months
after stroke (10, 11, 18). Our definition of the “early-start”
group generally aligns with the recently agreed definition of
the “subacute phase” as proposed by The Stroke Recovery and
Rehabilitation Roundtable taskforce (9). Most patients in the
early-start group were either in the “early subacute” phase (1
week to 3 months) or the “late subacute” phase (3–6 months).
Our findings show that patients treated in the subacute phase
experience at least a similar (and a tendency for better) benefit
than those treated in the chronic stages after stroke. Importantly,
we observed continued effectiveness and safety with repeat
treatments. Thus, as suggested by Rosales and colleagues (20), it
follows that patients who receive early treatment will gain more
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FIGURE 3 | Effects on pain (A) Descriptive statistics for pain score (VAS), early-start vs. delayed start subgroups (B) Patient quality of life (EQ-5D pain/discomfort
domain). Study visits were at end of treatment cycle. VAS, visual analog scale.
time living with reduced spasticity than if they were treated later
in their lifetime. In addition, the conditions for rehabilitation are
typically better in the subacute vs. the chronic phase. There is
evidence of continued neuroplasticity in the subacute phase, and
it is intuitively easier to treat a patient before the development
of intrinsic muscle changes and contractures that can worsen the
severity of spasticity (9, 11, 28–30). Indeed, we saw a significant
difference in PROM at the wrist joint between the early- and late-
start groups. This is of direct practical importance because many
of our patients were at risk of palmar flexion, which once the wrist
goes beyond 70◦, is hard to treat except by surgery. Further, it
has been suggested that starting treatment early may prevent the
development of secondary complications, allowing the spasticity
to be effectively managed with lower doses of BoNT (18). Our
findings support this concept of lower dosing in the subacute
phase and also indicate that the time between injections may be
longer in the earlier stages than the late stages.
The impact of previous treatment was highlighted by the
descriptive results when analyzed by prior exposure to BoNT
therapy. While there was a numerically larger reduction in
mean MASEWF scores in the early-start vs. late-start BoNT-
naïve patients, this pattern was not apparent in the previously-
treated patients, again supporting the effectiveness of an
early-start. Recent Phase III studies of repeat treatment with
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FIGURE 4 | Satisfaction with treatment. Study visits were at end of treatment cycle. Satisfied = satisfied + very satisfied; Dissatisfied = unsatisfied + very unsatisfied.
abobotulinumtoxinA have shown that spasticity parameters
continue to improve with repeat treatments (31), and our
observations in the treatment naïve patients suggest this may be
especially true in the earlier (i.e., first three or four) treatment
cycles where we saw a continual reduction inMAS scores–in both
the early and late start groups. MAS scores for the previously
treated patients were lower than for the BoNT-naïve group and
were relatively stable, indicating that they were already well-
managed. However, statistical significance between early- and
late- start of treatment in the ANCOVA model was not achieved
for BoNT-naïve patients, although this may also reflect the much
reduced sample size. Another limitation is that, in line with its
real-life design, we assessed MAS scores at end of treatment
cycle, rather than at peak effect. It is likely that measuring the
MAS and other parameters 3–4 months after injection when the
pharmacological effect is expected to be waning, might hide a
stronger effect of BoNT-A treatment during the treatment cycle.
Goal achievement was generally good in this study. Since
treatment goals are necessarily tailored to be appropriate for the
individual needs of the patient at the time of treatment, it is
perhaps to be expected that there were no significant differences
in goal achievement between the early- and late- start treatment
groups. Of interest, patients in the early-start group reported
higher pain scores and more frequently chose reduced pain
as a treatment goal than those in the late-start group. This is
noteworthy as pain in poststroke patients is often only associated
with contractures and painful postures in chronic spasticity,
which is less likely to be the cause of pain in the early-start
group. This is an important observation as stretch-related pain
is a common barrier to patient adherence with home-based
physiotherapy (32). Previous studies have shown beneficial effects
of BoNT-A on post-stroke pain (22, 33, 34), and our data extends
this finding to patients with early post-stroke spasticity and
particularly in the first abobotulinumtoxinA treatment cycle.
The reasons for this better effect in the first cycle merit further
exploration, but may include an indirect effect through reduction
of painful spasms (33).
A common indication for BoNT-A therapy is to reduce tone
in order to permit more effective OT and PT with respect to
gaining function (26). While the goal of improving ease of PT
or OT appeared to be more relevant for patients in the late-start
group, it is pertinent to note that this goal was significantly better
achieved in the early- than in the late-start of treatment group
(p = 0.04). There is some limited evidence that certain task-
based PT and OT approaches are more effective when started
earlier post-stroke than later, and it may be that earlier use of
BoNT-A may help patients make the most of an early window
of opportunity (35, 36). Moreover, the number of hours spent
at PT/OT reduced in the early compared to late group (mean
decrease of almost 1 h vs. an increase of almost 1 h). It may be
that BoNT-A injection (and study participation) caused some re-
energization in late-start patients to participate in OT and PT
programs. A limitation of this study is that we only considered
hours of therapy, and not type of therapy. Other ongoing studies,
such as the ULIS III program are currently collecting data to
address this important issue (37).
Satisfaction with treatment was generally good across the
whole patient cohort with few significant differences between
groups. Ratings of treatment satisfaction were generally similar
for patients, investigators and caregivers, although many
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caregivers were not assessed. This highlights the need for
including the caregivers in discussing treatment expectations as
well as providing caregiver support. Taken overall, we observed
a generally stronger increase in quality of life scores in the early-
start compared to the late-start group. In particular, patients in
the early-start group showed good improvements in self-care and
usual activities, whereas these domains remained more stable
in the middle and late-start groups. Quality of life in terms of
anxiety and depression domain scores improved in all patients
during the study; here a limitation of this routine-practice study
is that we cannot tease out the effects of the treatment from
external factors such as acceptance and learning to cope with
having spasticity. Other studies have found spasticity and social
needs to have the strongest impact on quality of life following a
stroke (38).
To our knowledge, this is the first prospective evaluation of
the long-term effectiveness of routine botulinum toxin treatment
on the recovery of upper limb spasticity in relation to the
time since stroke. Limitations of the study include the high
dropout rate primarily driven by loss to follow-up, with the
consequence of relatively small patient numbers, especially at
the later visits. As seen in the various analyses, prior exposure
to BoNT therapy appears to be an important confounder
of results. The study originally planned to primarily enroll
BoNT naive patients, but problems with recruitment meant
that the study had to be opened up to patients already under
treatment. Since this was an observational study, we did not
have complete datasets for each variable evaluated and it would
have also been valuable to include more patient reported
outcomes (as well as satisfaction with treatment) to give the
patients perspective on their spasticity management. Finally,
another important limitation is our quartile-based definition
of early-start treatment, where the mean time since stroke
was 3.2 months. This is just on the upper limits of the
study-based definitions for “very early intervention” where
botulinum toxin has been given within 2–12 weeks of the
event to try and target neutrally mediated spasticity (18–20).
Other factors having influenced the outcome might be the
measurement not at peak effect, but rather at the end of the
treatment effect and the shorter intervals and higher dose in
the late compared to the early group. This is an interesting
finding in itself, as it suggests similar or slightly better effects
can be obtained when treating early–even when saving toxin
and intervals.
CONCLUSION
Taken overall, the results of this study confirm the utility
of abobotulinumtoxinA injections at all stages of disease and
support the idea that all patients whose spasticity is troublesome
merit goal-directed treatment, regardless of whether it is started
in the early or latter stages of the patients disease journey.
Continuous treatment should be offered to patients where their
treatment goals are considered amenable to BoNT-A treatment.
Although our primary effectiveness analyses did not show a
significant difference between early- and late- start of treatment,
exploratory analyses in BoNT-naive patients showed a trend in
favor of early treatment that merits further exploration.
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